Business Wire

Desktop Metal Expands Global Partnership with SolidCAM to Four New Countries in the Americas, Europe and Asia

Share

Desktop Metal (NYSE: DM), a global leader in additive manufacturing technologies for mass production, today announced it has expanded its relationship with CNC software innovator SolidCAM, creator of the breakthrough iMachining® toolpath technology and a leading distributor of solutions to precision metal manufacturers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005464/en/

SolidCAM, which was founded in 1984, has offered Desktop Metal products in Germany since 2021. Now, it will offer Desktop Metal solutions for direct printing of metal to customers in the United States, where SolidCAM has technology centers at its US headquarters in Newton, Pa., and Rancho Cucamonga, CA, as well as the United Kingdom, Israel and India. In all, SolidCAM has about 100 direct sales team members worldwide.

Additionally, new CNC + AM Center of Excellence showrooms are currently being completed in Pennsylvania, Germany, and the UK to demonstrate how Desktop Metal’s AM 2.0 solutions complement traditional subtractive machining technology and workflows. Additional facilities are also slated for completion in California, Israel and India.

“The Desktop Metal team is delighted to announce an expansion of our relationship with SolidCAM, a brand that is long trusted by machinists worldwide,” said Ric Fulop, Founder and CEO of Desktop Metal. “This expanded partnership means that more CNC professionals will learn how easy it is to 3D print and sinter complex designs on our Studio System and Shop System metal AM offerings, freeing up capacity on CNC equipment, as well as machinist’s time. Additive manufacturing technology is truly complementary to machining, and we’re eager to deliver that message to the market in partnership with SolidCAM.”

“Our Schramberg Technology Center has already added a Desktop Metal Studio System to its current CNC machines, and we’re in the process of adding more Studio System and Shop System printers to our facilities worldwide so we can demonstrate how this additive manufacturing technology is complementary to CNC machining equipment,” said Dr. Emil Somekh, Founder and CEO of SolidCAM. “The growing impact of additive manufacturing has been well documented. During the COVID-19 epidemic, 3D printing played a critical role in repairing vulnerabilities in supply chains, especially in the medical sector, and we think it can help improve the throughput of supply chains that remain challenged today.”

SolidCAM will be showcasing Desktop Metal equipment and solutions in its booth at IMTS 2022 from Sept. 12 - 17 in Chicago in Booth No. 134502. Desktop Metal will also have two booths at the show, No. 433103 and 432212, where it will be showcasing its metal, polymer, and digital metal casting Additive Manufacturing 2.0 solutions. The International Manufacturing Technology Show, produced by the Association For Manufacturing Technology, is the largest and longest-running industry trade show in the Western Hemisphere.

About Desktop Metal

Desktop Metal, Inc., based in Burlington, Massachusetts, is accelerating the transformation of manufacturing with an expansive portfolio of 3D printing solutions, from rapid prototyping to mass production. Founded in 2015 by leaders in advanced manufacturing, metallurgy, and robotics, the company is addressing the unmet challenges of speed, cost, and quality to make additive manufacturing an essential tool for engineers and manufacturers around the world. Desktop Metal was selected as one of the world’s 30 most promising Technology Pioneers by the World Economic Forum, named to MIT Technology Review’s list of 50 Smartest Companies, and the 2021 winner of Fast Company’s Innovation by Design Award in materials and Fast Company’s Next Big Things in Tech Award for sustainability.

About SolidCAM

SolidCAM is recognized as the world leader in seamless integration of CAM in leading CAD products, SolidWorks and Inventor, supporting the complete range of CNC manufacturing applications, including iMachining 2D/3D, 2.5D milling, high-speed surface milling, 3D high-speed machining, multi-sided indexial 4/5 axes milling, simultaneous 5 axes milling, multi-channel mill-turn, Swiss-type machining and probing. SolidCAM has been a consistent growth leader in CAM. Along with its worldwide branches and affiliates direct sales channels, SolidCAM has a worldwide CAM reseller network, in over 50 countries. The SolidCAM industrial user base includes today more than 24,000 seats.

Forward-looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to, the risks and uncertainties set forth in Desktop Metal, Inc.'s filings with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sarah Webster
sarahwebster@desktopmetal.com
(724) 516-2336

SolidCAM
Shaun Mymudes
Shaun.m@solidcam.com
866-975-1115, x3

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye